Diranersen Missed Its Primary Endpoint. Biogen is Going to Phase 3 Anyway.

Biogen's tau-targeting ASO slowed AD cognitive decline "comparable to approved amyloid-targeting therapies." But the trial was halved mid-enrollment and no actual numbers have been released.